Detailed Narrative
Merger Announcement and Rationale
Dr. Agarwal's Health Care Limited (AHCL) announced the proposed merger of its subsidiary, Dr. Agarwal's Eye Hospital Limited (AEHL), into the parent entity. This strategic move is aimed at driving operational and financial efficiencies through streamlined functions and faster decision-making. Management highlighted that the merger will enable unified capital allocation, strengthen the balance sheet to support future growth, and provide a simplified legal, regulatory, and governance framework, reinforcing their commitment to long-term value creation for all stakeholders.
Transaction Details: Preferential Allotment
Prior to the merger, AHCL will make a preferential allotment of 1,32,827 equity shares of AEHL at a price of ₹5,270 per share, totaling approximately ₹70 crores. These funds are earmarked for AEHL's immediate CAPEX requirements, specifically for the construction of a flagship facility at Cathedral Road. Post-allotment, AEHL's total equity share capital will increase from 47 lakh shares to 48.3 lakh shares, with the promoter's holding rising from 71.9% to 72.7%, while public shareholding will dilute from 28.1% to 27.3%.
Transaction Details: Share Swap Ratio
The proposed merger involves a share swap ratio where AEHL shareholders will receive 23 equity shares of AHCL for every 2 shares held in AEHL. This ratio was recommended by independent valuers (PWC Business Consulting Services, LLP and Bansi S. Mehta Valuers, LLP) and supported by fairness opinions from SEBI-registered merchant bankers (Kotak Mahindra Capital Company for AHCL and Motilal Oswal Investment Advisors for AEHL). Management stated that this swap ratio implies a 15% premium for AEHL over its 10-day Volume Weighted Average Price (VWAP) of ₹4,554 per share.
Post-Merger Shareholding Structure
Following the merger, AEHL will be absorbed into AHCL, creating a single listed entity. AEHL's public shareholders will directly become shareholders of AHCL, holding a 4.6% stake in the combined entity. AHCL's public shareholding will see a dilution from 67.6% to 64.5%, while the promoter and promoter group will hold approximately 30.9% stake in the combined entity. The total share capital of the merged entity is projected to be approximately ₹33.13 crores.
Merger Timeline and Approvals
The implementation of the merger is expected to take approximately 12-14 months, subject to various requisite approvals. The process involves obtaining no-objection letters from stock exchanges and SEBI, followed by approval from the NCLT. A critical step will be shareholder and creditor meetings, where the scheme will require approval from a requisite majority, including the majority of minority shareholders of both AEHL and AHCL.
Analyst Concerns on Merger Ratio Fairness
Several analysts and individual investors expressed strong concerns regarding the fairness of the merger ratio to AEHL's minority shareholders. They argued that the ratio seemed 'very off' and 'unfair,' suggesting that basic financial analysis would indicate a higher valuation for AEHL. Questions were raised about the valuation methodologies used by the independent valuers and a potential conflict of interest with the merchant bankers providing fairness opinions. Management reiterated that a fair process was followed, adhering to high corporate governance standards, and offered to engage with AEHL minority shareholders offline to explain the valuation in detail.